In Reply Our cost-effectiveness analysis of multigene testing in 11 836 patients with breast cancer1 showed that unselected triple-gene testing for BRCA1, BRCA2, and PALB2 at breast cancer diagnosis would be cost-effective for the UK and US health systems, with incremental cost-effectiveness ratios of £10 464 or $65 661 per quality-adjusted life-year, respectively. Additionally, 1 year’s unselected genetic testing for BRCA1, BRCA2, and PALB2 could prevent 2101 cases of breast and ovarian cancer and 633 deaths in the UK and 9733 cases of breast and ovarian cancer and 2406 deaths in the US.1 Approximately 50% of pathogenic variant (formerly mutation) carriers are below the threshold for genetic testing used in most countries and are missed by current clinical criteria. Unselected testing will identify many more women at risk and provide a huge impetus for precision prevention and personalized treatment.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Manchanda R, Buist DSM, Evans DGR. Future Research Suggestions for Multigene Testing in Unselected Populations—Reply. JAMA Oncol. Published online March 26, 2020. doi:10.1001/jamaoncol.2020.0131
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: